Vol.

No.

June 02, 2023Jun 02, 2023

DOWNLOAD THE PDF

Robert Winn tells us how he led VCU Massey to obtain Comprehensive designation

Cover Story

Conversation with The Cancer Letter Free

Robert Winn tells us how he led VCU Massey to obtain Comprehensive designation

By Paul Goldberg

VCU Massey Cancer Center can now add the word “Comprehensive” to its name.

UCSD’s Comprehensive Cancer Center designation is in trouble; director Califano steps down amid turmoil

By Paul Goldberg

Conversation with The Cancer Letter Free

Richard Pazdur discusses root causes of cisplatin and carboplatin shortage and what can be done to alleviate it

By Paul Goldberg

Guest Editorial

Drug shortages threaten lives—cancer patients cannot wait

By Karen E. Knudsen

Guest Editorial

Sexual harassers should face consequences: As NIH director, Bertagnolli can foster change

By Shikha Jain

Clinical

ComboMATCH trial—a collaboration across NCI and NCTN groups—matches patients with combination therapy trials based on tumor biology

By Jacquelyn Cobb

Free In the Archives

Marcus Humphrey on the long road to diagnosis and successful treatment of lymphoma with CAR T-cell therapy

In Brief

Ezra Cohen named chief medical officer of oncology at Tempus

Crystal Rodriguez-Dabney named chief diversity officer and senior VP at Roswell Park

Sudhir Srivastava receives Ruth C. Brufsky Award for Excellence in Clinical Research in Pancreatic Cancer

Mary Daly receives BRCA Impact Award from UPenn Basser Center for BRCA

Paul Goldberg’s Cold War thriller released by FSG

Clinical Roundup

Keytruda + Lenvima demonstrates long-term, durable survival benefit vs. sunitinib as first-line treatment for advanced RCC in phase III trial

Preliminary results from phase I show safety and tolerability of Reqorsa + Tagrisso in NSCLC

Fox Chase study challenges assumptions about cystic renal masses

Drugs & Targets

FDA approves Lynparza with abiraterone, prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer

FDA approves Posluma—first radiohybrid PSMA-targeted PET imaging agent for prostate cancer

FDA grants priority review to repotrectinib for locally advanced or metastatic ROS1-positive NSCLC

EMA CHMP recommends approval of Opdivo + chemo for the neoadjuvant treatment of PD-L1 positive, resectable NSCLC at a high risk of recurrence

Lifebit, Flatiron Health partner to accelerate cancer data research

Leal Health establishes proprietary platform for oncologists to obtain personalized clinical trial matches for patients

NCI Trials

NCI Trials for June 2023

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Robert Winn tells us how he led VCU Massey to obtain Comprehensive designation

UCSD’s Comprehensive Cancer Center designation is in trouble; director Califano steps down amid turmoil

Richard Pazdur discusses root causes of cisplatin and carboplatin shortage and what can be done to alleviate it

Drug shortages threaten lives—cancer patients cannot wait

Sexual harassers should face consequences: As NIH director, Bertagnolli can foster change

ComboMATCH trial—a collaboration across NCI and NCTN groups—matches patients with combination therapy trials based on tumor biology

Marcus Humphrey on the long road to diagnosis and successful treatment of lymphoma with CAR T-cell therapy

In Brief

Ezra Cohen named chief medical officer of oncology at Tempus

Crystal Rodriguez-Dabney named chief diversity officer and senior VP at Roswell Park

Sudhir Srivastava receives Ruth C. Brufsky Award for Excellence in Clinical Research in Pancreatic Cancer

Mary Daly receives BRCA Impact Award from UPenn Basser Center for BRCA

Paul Goldberg’s Cold War thriller released by FSG

Clinical Roundup

Keytruda + Lenvima demonstrates long-term, durable survival benefit vs. sunitinib as first-line treatment for advanced RCC in phase III trial

Preliminary results from phase I show safety and tolerability of Reqorsa + Tagrisso in NSCLC

Fox Chase study challenges assumptions about cystic renal masses

Drugs & Targets

FDA approves Lynparza with abiraterone, prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer

FDA approves Posluma—first radiohybrid PSMA-targeted PET imaging agent for prostate cancer

FDA grants priority review to repotrectinib for locally advanced or metastatic ROS1-positive NSCLC

EMA CHMP recommends approval of Opdivo + chemo for the neoadjuvant treatment of PD-L1 positive, resectable NSCLC at a high risk of recurrence

Lifebit, Flatiron Health partner to accelerate cancer data research

Leal Health establishes proprietary platform for oncologists to obtain personalized clinical trial matches for patients

NCI Trials

NCI Trials for June 2023

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login